Hims & Hers Health (HIMS) stock has been one of 2025’s standout gainers, climbing nearly 108% year-to-date, fueled by strong subscriber growth and growing demand for its digital health offerings. The company posted impressive Q1 results in May, with revenue jumping 111% year-over-year to $586 million. However, the stock has come under pressure recently, sliding about 16% over the past month after Novo Nordisk (NVO) ended its distribution deal with the company, citing concerns over compounded versions of its weight-loss drug Wegovy. With the stock in focus, now’s a good time to take a closer look at who actually owns HIMS shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Now, according to TipRanks’ ownership page, public companies and individual investors own 59.23% of HIMS. They are followed by ETFs, mutual funds, insiders, and other institutional investors at 20.46%, 14.55%, 5.51%, and 0.24%, respectively.
Digging Deeper into Hims & Hers Health’s Ownership Structure
Looking closely at top shareholders, Vanguard owns the highest stake in HIMS at 8.16%. Next up is iShares, which holds a 7.04% stake in the company.
Among the top ETF holders, the iShares Core S&P Mid-Cap ETF (IJH) owns a 2.97% stake in HIMS stock, followed by the Vanguard Total Stock Market ETF (VTI), with a 2.55% stake.
Moving to mutual funds, Vanguard Index Funds holds about 6.99% of HIMS. Meanwhile, TIAA‑CREF Funds owns 1.34% of the company.
Is HIMS Stock a Good Buy?
Overall, Wall Street is sidelined on HIMS stock based on one Buy, seven Holds, and two Sell recommendations. The average HIMS stock price target of $41 indicates a downside risk of 18.75% from current levels.
